Thoratec (NASDAQ: THOR) commented on HeartMate II clinical data presented as part of the ENDURANCE destination therapy trial today at ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE